Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Session I: Cancer Immunoediting and Cancer and Inflammation

Cancer immunoediting: Recent progress in elimination and equilibrium

Mark J. Smyth, Janelle Sharkey, Jeremy B. Swann, Paul Bolitho and Michele W. L. Teng
Mark J. Smyth
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janelle Sharkey
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy B. Swann
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Bolitho
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele W. L. Teng
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Cancer immunoediting is the process by which immune system components protect the host against primary tumor development and/or enhance tumor escape either by sculpting tumor immunogenicity or attenuating anti-tumor immune responses. We have previously shown that lymphocyte perforin protects the host from developing spontaneous B cell lymphoma. We now show in a variety of oncogene- and irradiation-driven mouse models of cancer that perforin is an important suppressor of B cell malignancies. The immune system:tumor interactions are postulated to occur in three continuous phases: elimination, equilibrium, and escape. We have used injection of the carcinogen methylcholanthrene (MCA), a tumor induction model, to examine the role of a series of cell types and signalling molecules that suppress or promote tumor development in both the elimination and equilibrium phases. Regulatory T cells (Tregs) have been shown to be present in MCA-induced tumors and postulated to promote de novo tumor development, however previous studies employed anti-CD25 antibody that is known to additionally affect various effector lymphocyte populations. Here we have used various regimes to deplete CD4+, CD25+, FR4+, or FoxP3+ cells and shown that depletion of FR4+ or FoxP3+ cells alone at the time of tumor initiation provided the greatest protection from tumor development. Furthermore, protection appears intact in the absence of NK, CD8 or NKT cells, or perforin, DR5 or IFN-γ, and is only lost with the concurrent depletion of NK cells and CD8+ T cells or absence of both perforin and IFN-γ. These data illustrate the remarkable diversity of effector response suppressed by Tregs. Recently we demonstrated that MyD88-deficient mice were resistant to MCA-induced sarcoma. Candidate MyD88-dependent pathways of interest include IL-1 and many of the TLR. Now we show that early, but not late, neutralization of IL-1β also protected mice from sarcoma induction. For the first time using the MCA model our work has identified small inert lesions containing tumor cells in an equilibrium state. An attenuated dose of the carcinogen MCA causes an initial wave of tumors affecting a small proportion of mice, however the apparently healthy surviving mice harbor dormant tumors kept in check by adaptive IL-12/IFN-γ-dependent immunity. We have further explored temporal nature and other factors regulating this state of tumor:immune equilibrium as well as attempting to establish other mouse models of this state.

This project was supported by a NH&MRC of Australia Program Grant.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Mark J. Smyth
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cancer immunoediting: Recent progress in elimination and equilibrium
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
Citation Tools
Cancer immunoediting: Recent progress in elimination and equilibrium
Mark J. Smyth, Janelle Sharkey, Jeremy B. Swann, Paul Bolitho and Michele W. L. Teng
Cancer Immun January 1 2008 (8) (Suppl 2) 3;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cancer immunoediting: Recent progress in elimination and equilibrium
Mark J. Smyth, Janelle Sharkey, Jeremy B. Swann, Paul Bolitho and Michele W. L. Teng
Cancer Immun January 1 2008 (8) (Suppl 2) 3;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cancer immunoediting: Molecular pathways to possible novel therapeutic interventions
  • Balancing tumor immunity and inflammation
Show more Session I: Cancer Immunoediting and Cancer and Inflammation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement